TORONTO, ON — June 30, 2026 — Leads & Copy — Avicanna Inc., a biopharmaceutical company specializing in the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, has announced the promotion of Mr. Nick Hilborn to Chief Financial Officer (CFO), effective immediately. Hilborn has been with the company since July 2024, initially serving as Vice President of Finance before taking on the role of Interim CFO in September 2025. His prior experience includes positions at Telus, EY, and PwC.
Avicanna is an international biopharmaceutical firm focused on the global medical and pharmaceutical markets, with a specialization in proprietary and evidence-based cannabinoid products. The company has developed scientific and medical affairs platforms that support its four commercial-stage business pillars, leading to the introduction of over fifty finished products.
Among its commercial offerings is the medical cannabis formulary, RHO Phyto™, which provides a variety of proprietary products in oral, sublingual, topical, and transdermal formats with different cannabinoid ratios. This formulary is supported by ongoing patient and medical community education and is currently available across Canada, with plans for international expansion.
The company also operates the medical cannabis care platform, MyMedi.ca, designed to enhance the patient journey for medical cannabis users. Operated by Northern Green Canada Inc., MyMedi.ca offers a diverse product portfolio and bilingual, pharmacist-led patient support programs. It also provides specialty services for specific patient groups, such as veterans, and collaborates with payers for adjudication and reimbursement. Educational resources are available to the medical community to aid in the integration of medical cannabis into healthcare.
Avicanna is advancing a pharmaceutical pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These candidates aim to address unmet medical needs in dermatology, chronic pain, and neurological disorders, leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence.
Furthermore, the company produces active pharmaceutical ingredients through its majority-owned subsidiary, Santa Marta Golden Hemp SAS (SMGH). SMGH is a commercial-stage business supplying high-quality CBD, THC, and CBG to international partners for use in food, cosmetics, medical, and pharmaceutical products. SMGH also contributes to Avicanna’s supply chain, providing essential input products for its global consumer retail, medical cannabis, and pharmaceutical divisions.
Source: Avicanna Inc.
